Vlahos G - Search Results

1

Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.

Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A. Dimopoulos MA, et al. Among authors: vlahos g. Gynecol Oncol. 2004 Dec;95(3):695-700. doi: 10.1016/j.ygyno.2004.08.018. Gynecol Oncol. 2004. PMID: 15581984 Clinical Trial.

2

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.

Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA. Bamias A, et al. Among authors: vlahos g. BMC Cancer. 2006 Sep 25;6:228. doi: 10.1186/1471-2407-6-228. BMC Cancer. 2006. PMID: 16999858 Free PMC article.

3

Gynecologic oncology patients in the surgical high dependency unit: an analysis of indications.

Thomakos N, Zacharakis D, Rodolakis A, Zagouri F, Papadimitriou CA, Bamias A, Dimopoulos MA, Haidopoulos D, Vlahos G, Antsaklis A. Thomakos N, et al. Among authors: vlahos g. Arch Gynecol Obstet. 2014 Aug;290(2):335-9. doi: 10.1007/s00404-014-3180-1. Epub 2014 Mar 18. Arch Gynecol Obstet. 2014. PMID: 24639289

4

Do critical care units play a role in the management of gynaecological oncology patients? The contribution of gynaecologic oncologist in running critical care units.

Davidovic-Grigoraki M, Thomakos N, Haidopoulos D, Vlahos G, Rodolakis A. Davidovic-Grigoraki M, et al. Among authors: vlahos g. Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12438. Epub 2016 Jan 25. Eur J Cancer Care (Engl). 2017. PMID: 26805516 Review.

5

Prognostic value of preoperative Ca125 and Tag72 serum levels and their correlation to disease relapse and survival in endometrial cancer.

Myriokefalitaki E, Vorgias G, Vlahos G, Rodolakis A. Myriokefalitaki E, et al. Among authors: vlahos g. Arch Gynecol Obstet. 2015 Sep;292(3):647-54. doi: 10.1007/s00404-015-3675-4. Epub 2015 Mar 3. Arch Gynecol Obstet. 2015. PMID: 25731151

6

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA. Bamias A, et al. Among authors: vlahos g. Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28. Oncology. 2013. PMID: 23296063

7

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2.

Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Terpos E, Antsaklis A, Dimopoulos MA, Bamias A. Gavalas NG, et al. Among authors: vlahos g. Br J Cancer. 2012 Nov 20;107(11):1869-75. doi: 10.1038/bjc.2012.468. Br J Cancer. 2012. PMID: 23169339 Free PMC article.

8

A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.

Bamias A, Bamia C, Karadimou A, Soupos N, Zagouri F, Rodolakis A, Haidopoulos D, Vlahos G, Thomakos N, Antsaklis A, Dimopoulos MA. Bamias A, et al. Among authors: vlahos g. Oncology. 2011;81(5-6):365-71. doi: 10.1159/000334230. Epub 2012 Jan 13. Oncology. 2011. PMID: 22248920

9

Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.

Bamias A, Sotiropoulou M, Zagouri F, Trachana P, Sakellariou K, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA. Bamias A, et al. Among authors: vlahos g. Eur J Cancer. 2012 Jul;48(10):1476-83. doi: 10.1016/j.ejca.2011.09.023. Epub 2011 Oct 31. Eur J Cancer. 2012. PMID: 22047635

10

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2.

Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, Dimopoulos MA, Bamias A. Ziogas AC, et al. Among authors: vlahos g. Int J Cancer. 2012 Feb 15;130(4):857-64. doi: 10.1002/ijc.26094. Epub 2011 May 25. Int J Cancer. 2012. PMID: 21445972

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters